Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 4/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31468650 | 0.90 | KMT2A (0.41) | NR1H2NR1H3MEN1KMT2ADRD3 | |
| SCHEMBL31468622 | 0.88 | MEN1 (0.41) | MEN1KMT2ADRD2DRD3OPRM1 | |
| SCHEMBL31468562 | 0.85 | KMT2A (0.46) | MEN1KMT2A | |
| SCHEMBL31468517 | 0.83 | MEN1 (0.37) | MEN1KMT2ADRD2DRD3OPRM1 | |
| SCHEMBL31468459 | 0.82 | MEN1 (0.36) | MEN1KMT2ADRD2DRD3OPRM1 | |
| SCHEMBL19125392 | 0.80 | MEN1 (0.44) | MEN1KMT2ANR1I2GRM2GAA | |
| SCHEMBL16033355 | 0.80 | MEN1 (0.44) | MEN1KMT2ANR1I2GRM2GAA | |
| SCHEMBL16033157 | 0.77 | MEN1 (0.47) | MEN1KMT2ANR1I2GRM2GAA | |
| SCHEMBL31468644 | 0.76 | MEN1 (0.38) | MEN1KMT2ADRD2DRD3OPRM1 | |
| SCHEMBL609298 | 0.76 | MAPT (0.54) | MEN1KMT2ABCHENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4541800-A1 | NITROGEN-CONTAINING SILANE COMPOUND AND METHOD FOR PRODUCING SAME | Shin-Etsu Chemical Co., Ltd. (JP) | 2025-04-23 | — | — | EP | disclosed |
| US-20250122230-A1 | NITROGEN-CONTAINING SILANE COMPOUND AND METHOD FOR PRODUCING SAME | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122230-A1 | NITROGEN-CONTAINING SILANE COMPOUND AND METHOD FOR PRODUCING SAME | HRH3, HRH4, OR10J3 | NR1H2 72/4885NR1H3 53/4885MEN1 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.